Micomicen

Ciclopirox Olamine, the active ingredient in Micomicen, is an antifungal presented as a vaginal formulation for local use. It treats vulvovaginal candidiasis and related yeast infections in women.

GNH USA supplies Micomicen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Micomicen is an antifungal that acts on Candida species causing vaginal infections.

- Acute vulvovaginal candidiasis: reduces symptoms and eradicates the yeast infection. - Recurrent vulvovaginal candidiasis: helps decrease the frequency of breakthrough episodes. - Vulvar yeast infection: alleviates irritation and inflammation associated with Candida overgrowth.

Adverse reactions are generally limited to the site of application.

Common Side Effects: - Local irritation: mild burning or stinging sensation. - Itching: pruritus of the vaginal mucosa. - Discharge: increased vaginal secretions. - Unpleasant odor: temporary change in vaginal smell. - Mild abdominal discomfort: low‑grade pelvic pain. - Redness: erythema of the vulvar area.

Serious or Rare Side Effects: - Allergic reaction: rash, swelling, or hives. - Severe ulceration: painful sores in the vaginal tissue. - Stevens‑Johnson syndrome: rare, severe skin reaction. - Systemic hypersensitivity: anaphylaxis requiring emergency care.

Before using Micomicen, consider the following safety measures.

- Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Allergy: avoid if known hypersensitivity to ciclopirox or formulation components. - Concurrent vaginal products: do not use other intravaginal medications simultaneously without advice. - Immunocompromised patients: monitor closely for treatment response. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Micomicen may interact with other agents; monitor as indicated.

Major Interactions (Avoid): - Concurrent topical antifungals: may increase local irritation. - Systemic antifungal therapy: potential additive toxicity.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: no known effect, but monitor efficacy. - Antibiotics: may alter vaginal flora, watch for overgrowth. - Chemotherapeutic agents: monitor for mucosal toxicity.